...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
【24h】

The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.

机译：切除患者的生存状况非小细胞肺癌根据不同表皮生长因子受体突变和P21的表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aims of this study were to evaluate the prognostic implications of patients with epidermal growth factor receptor (EGFR) mutations and a p21 expression, and to determine their associations in resected non-small cell lung cancer (NSCLC) patients. We sequenced exons 18-21 of the EGFR tyrosine kinase domain by performing mutation analysis of tissues from patients that suffered with NSCLC and who also had undergone surgical resection. The expressions of p21 and p53 were analyzed using immunohistochemistry. We detected EGFR mutations in 24 of 97 patients (25%). EGFR mutations were more frequent in the people who had never smoked than in the smokers (33% versus 14%, respectively; P=.028). The presence of EGFR mutations had no effect on survival. The expression of p21 in the patients with wild-type EGFR tended to be associated with better survival. However, the expression of p21 in the patients with EGFR mutations was associated with poor overall survival (P=.006). The five-year survival rates were 17% for the patients with EGFR mutations and p21 positivity (Group I), 44% for the patients with wild type EGFR (Group II), and 75% for the patients with EGFR mutation and no p21 positivity (Group III) (P=.036). Multivariate analysis that was corrected for age, gender and cancer stage revealed different overall survival outcomes according to the three groups (P=.004). There was no significant correlation between the expressions of p21 and p53. Survival outcomes in the patients with resected NSCLC may be correlated with the presence of a p21 expression and EGFR mutations.
机译：本研究的目的是评估患者预后的影响表皮生长因子受体(EGFR)突变和p21的表达,来确定他们的协会在切除非小细胞肺癌癌症病人(NSCLC)。表皮生长因子受体酪氨酸激酶域的执行突变分析病人的组织与非小细胞肺癌,他也经历了手术切除。p53使用免疫组织化学进行了分析。检测表皮生长因子受体突变24的97名患者(25%)。从未吸过烟的人比吸烟者(分别为33%和14%;表皮生长因子受体突变没有影响生存。与野生型EGFR往往是相关的更好的生存。在患者表皮生长因子受体突变与贫穷的总生存期(P = .006)。五年存活率为17%表皮生长因子受体突变患者和p21积极性(我),44%的野生型患者表皮生长因子受体(组2),75%的患者表皮生长因子受体突变和p21积极性(第三组)(P = .036)。纠正对年龄、性别和癌症的阶段显示不同的整体生存的结果根据三组(P = 04)。没有明显的相关性p21和p53的表达。患者切除的非小细胞肺癌与p21的表达和表皮生长因子受体突变。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号